for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneron quarterly profit rises 45% on Eylea strength

Feb 5 (Reuters) - Regeneron Pharmaceuticals Inc on Friday reported a 45% rise in quarterly profit, benefiting from a recovery in demand for its flagship eye drug, Eylea, which took a hit last year due to the pandemic.

Net profit increased to $1.15 billion, or $10.24 per share, in the fourth quarter ended Dec. 31, from $792 million, or $6.93 per share, a year earlier. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up